代谢可塑性在肿瘤生长与转移中的研究进展

doi:10.11904/j.issn.1002-3070.2018.04.016

Abstract

Abstract: Cancer cells must change their metabolic activity to meet the energy needed for their rapid growth,metastasis,and biosynthesis.Different stages of tumor metastasis require the proliferation of cancer cells to make appropriate metabolic adjustments.This review summarizes primary tumor metabolism heterogeneity.At the same time,we summarize the changes in the metabolic strategies of primary tumor cells during metastasis and discuss metabolic changes of cancer that occur when cancer cells are colonized into different microenvironments as well as their mechanisms by which cells affect the metabolism of metastatic cells in metastatic sites.Through these discussions,we have clearly realized that the plasticity of tumor metabolism allows cancer cells to adapt and grow in unfavorable environments.The treatment of tumor metabolism is expected to become a treatment method to change the prognosis of tumor metastasis.

Key words: Tumor, Metastatic, Metabolism

CLC Number:

ZHANG Yiyun,WU Huaxing. Progress of metabolic plasticity in tumor growth and metastasis[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 362-366.

References

1 Yoshida GJ.Metabolic reprogramming:the emerging concept and associated therapeutic strategies[J].J Exp Clin Cancer Res,2015,34:111.
2 Lunt SY,Vander Heiden MG.Aerobic glycolysis:meeting the metabolic requirements of cell proliferation[J].Annu Rev Cell Dev Biol,2011,27:441-464.
3 Jose C,Bellance N,Rossignol R.Choosing between glycolysis and oxidative phosphorylation:a tumor's dilemma?[J].Biochim Biophys Acta,2011,1807(6):552-661.
4 Zhao Y,Liu Y,Lin L,et al.The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1[J].Mol Cancer,2018,17(1):69.
5 Guo X,Zhu Y,Hong X,et al.miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer[J].Cell Death Dis,2017,8(7):e2958.
6 Ma F,Zhang L,Ma L,et al.MiR-361-5p inhibits glycolytic metabolism,proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1[J].J Exp Clin Cancer Res,2017,36(1):158.
7 Wong N,Melo J,Tang D.PKM2,a central point of regulation in cancer metabolism[J].Cell Biol,2013,2013:242513.
8 Ganapathy-Kanniappan S,Geschwind JF.Tumor glycolysis as a target for cancer therapy:progress and prospects[J].Mol Cancer,2013,12:152.
9 Li Z,Zhang H.Reprogramming of glucose,fatty acid and amino acid metabolism for cancer progression[J].Cell Mol Life Sci,2016,73(2):377-392.
10 Sottnik JL,Lori JC,Rose BJ,et al.Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo[J].Clin Exp Metastasis,2011,28(8):865-875.
11 Elia I,Schmieder R,Christen S,et al.Organ-specific cancer metabolism and its potential for therapy[J].Handb Exp Pharmacol,2016,233:321-353.
12 MaR,Zhang W,Tang K,et al.Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma[J].Nat Commun,2013,4:2508.
13 Amann T,Hellerbrand C.GLUT1 as a therapeutic target in hepatocellular carcinoma[J].Expert Opin Ther Targets,2009,13(12):1411-1427.
14 Cui R,Shi XY.Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value[J].Int J Clin Exp Pathol,2015,8:11393-11399.
15 Notarnicola M,Messa C,Caruso MG.A significant role of lipogenic enzymes in colorectal cancer[J].Anticancer Res,2012,32(7):2585-2590.
16 Huang F,Zhang Q,Ma H,et al.Expression of glutaminase is upregulated in colorectal cancer and of clinical significance[J].Int J Clin Exp Pathol,2014,7(3):1093-1100.
17 Hussien R,Brooks GA.Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines[J].Physiol Genomics,2011,43(5):255-264.
18 Cao MD,Lamichhane S,Lundgren S,et al.Metabolic characterization of triple negative breast cancer[J].BMC Cancer,2014,14:941.
19 Kung HN,Marks JR,Chi JT.Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia[J].PLoS Genet,2011,7(8):e1002229.
20 Tchou J,Sonnad SS,Bergey MR,et al.Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer[J].Mol Imaging Biol,2010,12(6):657-662.
21 Santidrian AF,Matsuno-Yagi A,Ritland M,et al.Mitochondrial complex I activity and NAD/NADH balance regulate breast cancer progression[J].J Clin Invest,2013,123(3):1068-1081.
22 Ben Sahra I,Tanti JF,Bost F.The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells[J].Autophagy,2010,6(5):670-671.
23 Minamimoto R,Uemura H,Sano F,et al.The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level[J].Ann Nucl Med,2011,25(1):21-27.
24 Pertega-Gomes N,Vizcaino JR,Attig J,et al.Alactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer[J].BMC Cancer,2014,14:352.
25 Zadra G,Photopoulos C,Loda M.The fat side of prostate cancer[J].Biochim Biophys Acta,2013,1831(10):1518-1532.
26 Sonveaux P,Vegran F,Schroeder T,et al.Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice[J].J Clin Invest,2008,118(12):3930-3942.
27 Quail DF,Joyce JA.Microenvironmental regulation of tumor progression and metastasis[J].Nat Med,2013,19(11):1423-1437.
28 Xing Y,Zhao S,Zhou BP,et al.Metabolic reprogramming of the tumour microenvironment[J].FEBS J,2015,282(20):3892-3898.
29 Haschemi A,Kosma P,Gille L,et al.The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism[J].Cell Metab,2012,15(6):813-826.
30 Chang CH,Qiu J,O'Sullivan D,et al.Metabolic competition in the tumor microenvironment is a driver of cancer progression[J].Cell,2015,162(6):1229-1241.
31 Ho PC,Bihuniak JD,Macintyre AN,et al.Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses[J].Cell,2015,162(6):1217-1228.
32 LeBleu VS,O'Connell JT,Gonzalez Herrera KN,et al.PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis[J].Nat Cell Biol,2014,16(10):992-1003.
33 Yuneva MO,Fan TW,Allen TD,et al.The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type[J].Cell Metab,2012,15(2):157-170.
34 Mashimo T,Pichumani K,Vemireddy V,et al.Acetate is a bioenergetic substrate for human glioblastoma and brain metastases[J].Cell,2014,159(7):1603-1614.
35 Loo JM,Scherl A,Nguyen A,et al.Extracellular metabolic energetics can promote cancer progression[J].Cell,2015,160(3):393-406.
36 Fong MY,Zhou W,Liu L,et al.Breast cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis[J].Nat Cell Biol,2015,17(2):183-194.

[1]	ZHANG Maoxiang,SUN Huixin,SONG Bingbing. Analysis of the incidence and mortality of malignant tumors in Daoli District,Harbin,2008—2012 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 261-265.
[2]	LIU Yishu,QU Guofan. Progress in long-chain non-coding RNA in osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 266-270.
[3]	HOU Yuxue,LI Xiaoli. The research progress of Wnt7a and malignant tumors,and its relationship [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 271-275.
[4]	XU Hui, LI Xi, ZHOU Chunshui. Screening of lung cancer tumor-associated suppressor genes using shRNA library targeting human transcriptome [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 97-102.
[5]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[6]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[7]	TONG Guanghai, TIAN Yang, WU Huaxing. Application of lipidomics in colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 179-192.
[8]	YUAN Guixia, LI Yan, FENG Wanqi, XIA Xiaojuan, LI Xu. Mechanism of tumor suppressor gene DKK2 inhibiting proliferation of nephroblastoma cells in children [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 14-20.
[9]	DING Jiexian, ZHANG Jin, CHEN Yonggang, WANG Xingwen, WANG Shuanke. Progress in Wnt signaling pathway and tumorigenesis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 73-77.
[10]	KAN Jun, ZHOU Daihan, ZHANG Enxin. Research progress in tumor with cardiovascular disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 558-561.
[11]	LIU Juan, ZHANG Shutian. Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 575-578.
[12]	LI Yue, XU Ke, HAN Zengxiang, SUN Min, FAN Guohua, ZHANG Yong. Advances in the role of tumor-associated macrophage in colon cancer and targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 450-454.
[13]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[14]	ZHANG Yali, SU Danke. Research progress in gadolinium-based molecular probes for tumor targeting imaging [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 460-463.
[15]	HAN Bangling, WANG Yimin, XUE Yingwei. Research progress of vitamin D in tumors of digestive system [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 471-475.

Progress of metabolic plasticity in tumor growth and metastasis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments